Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bristol-Myers Squibb
Age
18–70
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Male and female subjects aged 18 to 70 years, with hepatic impairment conforming to Child-Pugh class A, B or C
Healthy subjects to the extent possible matched to the first four hepatically impaired subject in each Child-Pugh class with regard to age (approximately ± 10 years), body weight (approximately ± 20%) and gender
You may not be if
History of esophageal and gastric variceal bleeding within past 6 months
Primarily cholestatic liver diseases
Active alcoholic hepatitis
Stable encephalopathy of \>= Stage 2
Presence of severe ascites or edema
Presence of hepatopulmonary or hepatorenal syndrome
Positive for HCV, unless HCV RNA is undetectable
Clareo Health | Single-Dose Pharmacokinetics of BMS-790052 in Participants With Hepatic Impairment
